A post-treatment blood test could inform future cancer therapy decisions
In the continuing evolution of personalized medicine, a new study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment. This tool is a type of molecular residual disease (MRD)detector, which is used after patients have completed their primary treatment in order to monitor their cancer status. Researchers say it could inform clinical intervention, including whether to restart or intensify treatment.
admin
0
1
In the continuing evolution of personalized medicine, a new study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment. This tool is a type of molecular residual disease (MRD)detector, which is used after patients have completed their primary treatment in order to monitor their cancer status. Researchers say it could inform clinical intervention, including whether to restart or intensify treatment.
